CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. (Q39861105)

15 September 2017

CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. (English)

1 reference

15 September 2017

pneumococcal infection

1 reference

Ju Cao

1

1 reference

15 September 2017

Yi Gong

2

1 reference

15 September 2017

Dairong Li

3

1 reference

15 September 2017

Nanlin Yin

4

1 reference

15 September 2017

Tingmei Chen

5

1 reference

15 September 2017

Wenchun Xu

6

1 reference

15 September 2017

Xuemei Zhang

7

1 reference

15 September 2017

Yibing Yin

8

1 reference

15 September 2017

language of work or name

English

0 references

publication date

10 March 2009

1 reference

15 September 2017

1 reference

15 September 2017

27

1 reference

15 September 2017

2838-2844

1 reference

15 September 2017

21

1 reference

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Prevention of pneumococcal disease by vaccination: does serotype replacement matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Streptococcus pneumoniae surface-exposed glutamyl tRNA synthetase, a putative adhesin, is able to induce a partially protective immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Induction of CC and CXC chemokines in human antigen-presenting dendritic cells by the pneumococcal proteins pneumolysin and CbpA, and the role played by toll-like receptor 4, NF-kappaB, and mitogen-activated protein kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Tissue-specific contributions of pneumococcal virulence factors to pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Microarray analysis of pneumococcal gene expression during invasive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Interleukin-17A mediates acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

CD4 T cells: fates, functions, and faults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Induction of secretory immunity and memory at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Harnessing invariant NKT cells in vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

TH17 cells in the big picture of immunology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

inferred from DOI database lookup

7 January 2021

based on heuristic

Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.093

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.02.093

1 reference

15 September 2017

1 reference